Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset

SARS‐CoV‐2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID‐19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust...

Descripción completa

Detalles Bibliográficos
Autores principales: Figueiredo‐Campos, Patrícia, Blankenhaus, Birte, Mota, Catarina, Gomes, Andreia, Serrano, Marta, Ariotti, Silvia, Costa, Catarina, Nunes‐Cabaço, Helena, Mendes, António M., Gaspar, Pedro, Pereira‐Santos, M. Conceição, Rodrigues, Fabiana, Condeço, Jorge, Escoval, M. Antonia, Santos, Matilde, Ramirez, Mario, Melo‐Cristino, José, Simas, J. Pedro, Vasconcelos, Eugenia, Afonso, Ângela, Veldhoen, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Immunity to infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756220/
https://www.ncbi.nlm.nih.gov/pubmed/33084029
http://dx.doi.org/10.1002/eji.202048970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756220/
https://www.ncbi.nlm.nih.gov/pubmed/33084029
http://dx.doi.org/10.1002/eji.202048970

Ejemplares similares